查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2023932

精準醫療市場預測至2034年－全球分析（按組件、產品類型、技術、定序技術、治療方法、給藥途徑、應用、最終用戶、分銷管道和地區分類）

Precision Medicine Market Forecasts to 2034 - Global Analysis By Component, Product Type, Technology, Sequencing Technology, Therapeutic Approach, Route of Administration, Application, End User, Distribution Channel, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球精準醫療市場規模將達到 1,102 億美元，並在預測期內以 10.7% 的複合年成長率成長，到 2034 年將達到 2,487 億美元。

精準醫療是醫療保健領域的創新方法，它根據每位患者的個別特徵（包括基因組成、環境因素和生活方式）最佳化醫療保健和預防策略。這種模式轉移超越了傳統的、統一的模式，能夠實現更精準的診斷、標靶治療並改善患者預後。該市場涵蓋伴隨診斷、基因組定序、生物資訊學和標靶治療，這些技術正在不同的醫療保健環境中得到應用，為腫瘤學、神經病學、心臟病學和罕見病管理等領域提供個人化醫療服務。

基因組定序技術的快速發展

全基因組定序成本的降低使得基因資訊的取得更加普及，從根本上改變了臨床決策能力。新一代定序平台能夠在數天內提供全面的基因組圖譜，且價格已達到常規臨床實踐可承受的水平，使醫生能夠識別致病突變並選擇最佳標靶治療。這項技術進步正在加速基因組數據融入標準腫瘤治療流程，使腫瘤分析能夠直接影響治療選擇。大規模基因組資料庫的日益普及進一步增強了識別新型生物標記和藥物標靶的能力，從而形成發現與臨床應用的良性循環，推動市場持續成長。

標靶治療和伴隨診斷高成本

儘管基因定序成本正在下降，但精準醫療的總成本對全球許多醫療系統和患者而言仍然高昂。新型標靶治療的年費用通常超過10萬美元，而伴隨診斷測試則進一步加重了經濟負擔。健保報銷系統難以跟上快速發展的技術步伐，導致醫保覆蓋缺口和預核准障礙，延誤了病患的就醫。在資源匱乏、基因檢測和專業治療基礎設施不完善的地區，醫療經濟挑戰更加嚴峻。這些經濟障礙有可能加劇醫療資源分配不均，並將精準醫療的益處主要限制在已開發國家資金雄厚的醫療體系中。

將人工智慧融入基因組分析

人工智慧正在革新複雜基因組數據的分析方式，它能夠快速識別出人類分析師常常忽略的、具有臨床應用價值的突變。基於海量資料集訓練的機器學習演算法能夠以越來越高的準確度預測疾病風險、治療反應和潛在副作用，從而加速將基因發現應用於臨床實踐。人工智慧平台整合了包括基因組學、蛋白質組學和代謝體學在內的多體學數據，建構全面的患者畫像，輔助治療決策。這些技術的整合將分析時間從數週縮短至數小時，降低了分析成本，並將基因檢測的臨床效用擴展到更廣泛的患者群體和疾病類別。

對資料隱私和基因歧視的擔憂

收集和儲存高度敏感的基因資訊會帶來重大的隱私風險，這可能會損害患者的信任，並阻礙他們參與精準醫療。儘管某些司法管轄區提供法律保護，但未授權存取基因組資料仍可能導致雇主、保險公司或其他機構的歧視。醫療保健系統內發生的多起重大資料外洩事件加劇了公眾對基因資訊安全的擔憂。利用新的計算方法重新識別匿名基因組資料的可能性進一步增加了隱私保護工作的複雜性。這些擔憂可能會降低患者接受基因檢測或向研究資料庫貢獻資料的意願，從而可能減緩對精準醫療發展至關重要的多樣化資料集的累積。

新冠疫情的影響

新冠疫情加速了精準醫療的普及，凸顯了快速基因組監測和個人化風險評估在人群層面的價值。基因組定序實現了病毒變異的即時追蹤，而基因生物標記有助於識別重症高風險患者，從而指導治療優先順序。疫情雖然擾亂了非新冠相關的臨床檢測，並延誤了許多精準腫瘤治療，但也促進了對分散式臨床研究基礎設施的投資。遠端醫療的擴展使得遠距基因諮詢和病患監測成為可能，從而擴大了精準醫療服務的覆蓋範圍。這些營運調整已被證明是永續的，後疫情時代的醫療體係也持續保持在多個疾病領域提供個人化醫療的增強能力。

在預測期內，製藥和生物技術公司細分市場預計將佔據最大的市場佔有率。

在預測期內，製藥和生物技術公司預計將佔據最大的市場佔有率。這主要得益於它們在標靶治療研發和伴隨診斷整合方面的大量投資。這些公司是精準醫療創新的關鍵促進者，它們投入巨額研發預算用於生物標記發現、基因組檢驗研究以及包含患者分層的臨床試驗設計。標靶癌症療法需要進行基因檢測以篩選患者，這從根本上改變了藥物研發的經濟模式，伴隨診斷也成為監管申報的標配。為了在這個快速發展的環境中保持主導地位，大型製藥企業正在建立專門的精準醫療部門，與診斷公司合作，並收購基因組技術公司。

在預測期內，線上平台產業預計將呈現最高的複合年成長率。

在預測期內，線上平台細分市場預計將呈現最高的成長率，這反映了精準醫療和消費者互動領域的數位轉型。消費者基因檢測服務使數百萬人能夠獲得個人化的健康訊息，從而催生了對後續臨床應用和結果解讀服務的需求。如今，電子商務平台無需傳統醫療中介機構即可提供個人化的營養補充方案、藥物基因檢測和客製化的健康計畫。與遠端醫療的整合使得遠距基因諮詢和虛擬精準腫瘤學會診成為可能，從而擴大了服務涵蓋範圍，並惠及更多服務不足的人。數位分銷管道的便利性、可近性和可擴展性，以及消費者對線上醫療服務日益成長的接受度，將在整個預測期內推動該細分市場的顯著成長。

市佔率最大的地區

在預測期內，北美地區預計將佔據最大的市場佔有率，這得益於公共和私人部門對基因組研究基礎設施和精準醫療舉措的大量投資。美國在核准伴隨診斷核准和標靶治療保險報銷的法規結構方面處於主導地位，從而為創新應用創造了有利的市場環境。該地區聚集了許多大型製藥公司總部、頂尖大學醫院以及強大的生物技術Start-Ups生態系統，促進了合作研究和技術的快速實用化。高人均醫療保健支出，加上病人權益倡導組織對個人化醫療方法的推廣，確保了對精準醫療服務的持續需求。諸如「全民研究計畫」（All of Us Research Initiative）等政府計畫正在進一步加速不同族群的資料收集和臨床應用。

複合年成長率最高的地區

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於其龐大且遺傳多樣性高的人口、醫療數位化進程的推進以及政府主導的舉措。中國、印度、日本和韓國正在啟動雄心勃勃的國家級精準醫療項目，並大力投資定序基礎設施和生物樣本庫建設。人口快速老化催生了對標靶癌症和神經退化性疾病治療的迫切需求，而中產階級收入的成長也推動了醫療支出的增加。在智慧財產權架構和臨床試驗能力的完善支持下，區域製藥公司正從學名藥生產轉向新型標靶治療的研發。歐美領導企業與亞太地區研究機構之間的策略合作，正進一步加速區域市場成長和臨床應用。

免費客製化服務

所有購買此報告的客戶均可享受以下免費自訂選項之一。

  • 企業概況
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 我們根據客戶要求提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 透過產品系列、地理覆蓋範圍和策略聯盟對標主要企業。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 成長機會和重點投資領域
  • 工業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球精準醫療市場：依組成部分分類

  • 軟體
  • 硬體
  • 服務

第6章 全球精準醫療市場：依產品類型分類

  • 消耗品
  • 裝置
  • 檢測和試劑盒

第7章 全球精準醫療市場：依技術分類

  • 基因組學
  • 轉錄組學
  • 表觀基因
  • 生物資訊學
  • 巨量資料分析
  • 伴隨診斷
  • 藥物發現技術
  • 生物標記檢測
  • 其他

第8章 全球精準醫療市場：依定序技術分類

  • 合成定序
  • 離子半導體序列
  • 連接定序
  • 焦磷酸測序
  • 單分子即時定序
  • 鏈終止序列
  • 奈米孔定序

第9章 全球精準醫療市場：依治療方法分類

  • 標靶治療
  • 免疫療法
  • 基因治療
  • 細胞療法
  • 單株抗體
  • 其他治療方法

第10章 全球精準醫療市場：依給藥途徑分類

  • 口服
  • 注射

第11章 全球精準醫療市場：依應用領域分類

  • 腫瘤學
  • 神經病學
  • 免疫學
  • 呼吸系統疾病
  • 感染疾病
  • 循環系統
  • 胃腸病學
  • 罕見遺傳疾病
  • 其他

第12章 全球精準醫療市場：依最終用戶分類

  • 醫院和診所
  • 臨床檢查室
  • 製藥和生物技術公司
  • 診斷公司
  • 研究和學術機構
  • 醫療保健IT公司
  • 其他

第13章 全球精準醫療市場：依分銷管道分類

  • 直銷
  • 第三方經銷商
  • 線上平台

第14章 全球精準醫療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 其他
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲地區

第15章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第16章：產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第17章：公司簡介

  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Thermo Fisher Scientific Inc.
  • Illumina Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • Siemens Healthineers AG
  • Bio-Rad Laboratories Inc.
  • Agilent Technologies Inc.
  • Quest Diagnostics Incorporated
  • Guardant Health Inc.
  • Exact Sciences Corporation
  • Foundation Medicine Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
Product Code: SMRC35143

According to Stratistics MRC, the Global Precision Medicine Market is accounted for $110.2 billion in 2026 and is expected to reach $248.7 billion by 2034 growing at a CAGR of 10.7% during the forecast period. Precision medicine represents a transformative approach to healthcare that tailors medical treatments and prevention strategies to individual patient characteristics, including genetic makeup, environmental factors, and lifestyle choices. This paradigm shift moves beyond the traditional one-size-fits-all model, enabling more accurate diagnoses, targeted therapies, and improved patient outcomes. The market encompasses companion diagnostics, genomic sequencing, bioinformatics, and targeted therapeutics deployed across diverse healthcare settings to deliver personalized care across oncology, neurology, cardiology, and rare disease management.

Market Dynamics:

Driver:

Rapid advancements in genomic sequencing technologies

Declining costs of whole-genome sequencing have democratized access to genetic information, fundamentally transforming clinical decision-making capabilities. Next-generation sequencing platforms now deliver comprehensive genomic profiles within days at prices accessible to routine clinical practice, enabling physicians to identify disease-causing mutations and select optimal targeted therapies. This technological evolution has accelerated the integration of genomic data into standard oncology care, where tumor profiling directly informs treatment selection. The increasing availability of large-scale genomic databases further enhances the ability to identify novel biomarkers and drug targets, creating a virtuous cycle of discovery and clinical application that drives sustained market expansion.

Restraint:

High costs of targeted therapies and companion diagnostics

Despite declining sequencing costs, the overall expense of precision medicine remains prohibitive for many healthcare systems and patients worldwide. Novel targeted therapies often carry price tags exceeding six figures annually, while companion diagnostic tests add further financial burden. Reimbursement frameworks struggle to keep pace with rapidly evolving technologies, creating coverage gaps and prior authorization hurdles that delay patient access. Health economic challenges intensify in resource-limited settings where infrastructure for genetic testing and specialized treatments remains underdeveloped. These financial barriers risk exacerbating healthcare disparities, limiting precision medicine benefits primarily to affluent populations and well-funded healthcare systems in developed nations.

Opportunity:

Integration of artificial intelligence in genomic interpretation

Artificial intelligence is revolutionizing the analysis of complex genomic data by rapidly identifying clinically actionable variants that human analysts might overlook. Machine learning algorithms trained on massive datasets can predict disease risk, treatment response, and potential adverse reactions with increasing accuracy, accelerating the translation of genetic discoveries into clinical practice. AI-powered platforms integrate multi-omic data including genomics, proteomics, and metabolomics to provide holistic patient profiles that inform treatment decisions. This technological convergence reduces interpretation time from weeks to hours, lowers analysis costs, and expands the clinical utility of genetic testing across broader patient populations and disease categories.

Threat:

Data privacy and genetic discrimination concerns

The collection and storage of sensitive genetic information raises significant privacy risks that could undermine patient trust and participation in precision medicine initiatives. Unauthorized access to genomic data could lead to discrimination by employers, insurers, or other entities, despite existing legal protections in some jurisdictions. High-profile data breaches across healthcare systems have heightened public anxiety about genetic information security. The potential for re-identification of de-identified genomic data through emerging computational methods further complicates privacy protection efforts. These concerns may reduce patient willingness to undergo genetic testing or contribute to research databases, slowing the accumulation of diverse datasets essential for precision medicine advancement.

Covid-19 Impact:

The COVID-19 pandemic accelerated precision medicine adoption by demonstrating the value of rapid genomic surveillance and personalized risk assessment at population scale. Genomic sequencing enabled real-time tracking of viral variants, while genetic biomarkers helped identify patients at highest risk for severe outcomes, guiding treatment prioritization. The pandemic disrupted non-COVID clinical trials and delayed many precision oncology procedures, but simultaneously catalyzed investments in decentralized clinical research infrastructure. Telehealth expansion enabled remote genetic counseling and patient monitoring, expanding access to precision medicine services. These operational adaptations have proven durable, with post-pandemic healthcare systems maintaining enhanced capabilities for personalized care delivery across multiple disease areas.

The Pharmaceutical & Biotechnology Companies segment is expected to be the largest during the forecast period

The Pharmaceutical & Biotechnology Companies segment is expected to account for the largest market share during the forecast period, driven by substantial investments in targeted therapy development and companion diagnostic integration. These organizations serve as primary drivers of precision medicine innovation, dedicating significant research budgets to biomarker discovery, genomic validation studies, and clinical trial designs incorporating patient stratification. The shift toward targeted oncology drugs requiring genetic testing for patient selection has fundamentally altered drug development economics, with companion diagnostics becoming standard components of regulatory submissions. Major pharmaceutical players have established dedicated precision medicine units, forged partnerships with diagnostic companies, and acquired genomic technology firms to secure leadership positions in this rapidly evolving landscape.

The Online Platforms segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Online Platforms segment is predicted to witness the highest growth rate, reflecting the digital transformation of precision medicine delivery and consumer engagement. Direct-to-consumer genetic testing services have familiarized millions with personalized health insights, creating demand for follow-up clinical applications and interpretation services. E-commerce platforms now facilitate access to personalized supplement regimens, pharmacogenetic testing, and customized wellness programs without traditional healthcare intermediaries. Telemedicine integration enables remote genetic counseling and virtual precision oncology consultations, expanding reach to underserved populations. The convenience, accessibility, and scalability of digital distribution channels, combined with growing consumer comfort with online health services, position this segment for exceptional growth throughout the forecast period.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by substantial public and private investment in genomic research infrastructure and precision medicine initiatives. The United States leads in regulatory frameworks supporting companion diagnostic approval and targeted therapy reimbursement, creating favorable market conditions for innovation adoption. Major pharmaceutical headquarters, leading academic medical centers, and a robust biotechnology startup ecosystem concentrate within this region, fostering collaborative research and rapid technology translation. High healthcare spending per capita, combined with patient advocacy groups promoting personalized approaches, ensures sustained demand for precision medicine services. Government programs like the All of Us Research Initiative further accelerate data collection and clinical implementation across diverse populations.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by large and genetically diverse populations, increasing healthcare digitization, and government-backed genomics initiatives. China, India, Japan, and South Korea have launched ambitious national precision medicine programs, investing heavily in sequencing infrastructure and biobank development. Rapidly aging populations create urgent demand for targeted oncology and neurodegenerative disease treatments, while rising middle-class incomes enable greater healthcare spending. Regional pharmaceutical companies are shifting from generic manufacturing toward novel targeted therapy development, supported by improving intellectual property frameworks and clinical trial capabilities. Strategic partnerships between Western precision medicine leaders and Asia Pacific research institutions further accelerate regional market growth and clinical implementation.

Key players in the market

Some of the key players in Precision Medicine Market include Roche Holding AG, Novartis AG, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Thermo Fisher Scientific Inc., Illumina Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Quest Diagnostics Incorporated, Guardant Health Inc., Exact Sciences Corporation, Foundation Medicine Inc., Bristol-Myers Squibb Company, and AstraZeneca PLC.

Key Developments:

In April 2026, J&J's Innovative Medicine unit received a permanent billing code for INLEXZO, a targeted intravesical system for bladder cancer, streamlining patient access to this precision treatment.

In February 2026, Thermo Fisher expanded its real-world data capabilities through a collaboration with Datavant, aiming to link genomic data with clinical outcomes to support precision medicine research.

In October 2025, Roche entered into a strategic partnership to integrate AI-driven digital pathology with its diagnostic platforms to improve the accuracy of companion diagnostics for breast and lung cancers.

Components Covered:

  • Software
  • Hardware
  • Services

Product Types Covered:

  • Consumables
  • Instruments
  • Assays & Kits

Technologies Covered:

  • Genomics
  • Transcriptomics
  • Epigenomics
  • Bioinformatics
  • Big Data Analytics
  • Companion Diagnostics
  • Drug Discovery Technologies
  • Biomarker Detection
  • Other Technologies

Sequencing Technologies Covered:

  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Sequencing by Ligation
  • Pyrosequencing
  • Single Molecule Real-Time Sequencing
  • Chain Termination Sequencing
  • Nanopore Sequencing

Therapeutic Approaches Covered:

  • Targeted Therapy
  • Immunotherapy
  • Gene Therapy
  • Cell Therapy
  • Monoclonal Antibodies
  • Other Therapeutic Approaches

Route of Administrations Covered:

  • Oral
  • Injectable

Applications Covered:

  • Oncology
  • Neurology
  • Immunology
  • Respiratory Diseases
  • Infectious Diseases
  • Cardiology
  • Gastroenterology
  • Rare Genetic Diseases
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Clinical Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Companies
  • Research & Academic Institutes
  • Healthcare IT Companies
  • Other End Users

Distribution Channels Covered:

  • Direct Sales
  • Third-Party Distributors
  • Online Platforms

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Precision Medicine Market, By Component

  • 5.1 Software
  • 5.2 Hardware
  • 5.3 Services

6 Global Precision Medicine Market, By Product Type

  • 6.1 Consumables
  • 6.2 Instruments
  • 6.3 Assays & Kits

7 Global Precision Medicine Market, By Technology

  • 7.1 Genomics
  • 7.2 Transcriptomics
  • 7.3 Epigenomics
  • 7.4 Bioinformatics
  • 7.5 Big Data Analytics
  • 7.6 Companion Diagnostics
  • 7.7 Drug Discovery Technologies
  • 7.8 Biomarker Detection
  • 7.9 Other Technologies

8 Global Precision Medicine Market, By Sequencing Technology

  • 8.1 Sequencing by Synthesis
  • 8.2 Ion Semiconductor Sequencing
  • 8.3 Sequencing by Ligation
  • 8.4 Pyrosequencing
  • 8.5 Single Molecule Real-Time Sequencing
  • 8.6 Chain Termination Sequencing
  • 8.7 Nanopore Sequencing

9 Global Precision Medicine Market, By Therapeutic Approach

  • 9.1 Targeted Therapy
  • 9.2 Immunotherapy
  • 9.3 Gene Therapy
  • 9.4 Cell Therapy
  • 9.5 Monoclonal Antibodies
  • 9.6 Other Therapeutic Approaches

10 Global Precision Medicine Market, By Route of Administration

  • 10.1 Oral
  • 10.2 Injectable

11 Global Precision Medicine Market, By Application

  • 11.1 Oncology
  • 11.2 Neurology
  • 11.3 Immunology
  • 11.4 Respiratory Diseases
  • 11.5 Infectious Diseases
  • 11.6 Cardiology
  • 11.7 Gastroenterology
  • 11.8 Rare Genetic Diseases
  • 11.9 Other Applications

12 Global Precision Medicine Market, By End User

  • 12.1 Hospitals & Clinics
  • 12.2 Clinical Laboratories
  • 12.3 Pharmaceutical & Biotechnology Companies
  • 12.4 Diagnostic Companies
  • 12.5 Research & Academic Institutes
  • 12.6 Healthcare IT Companies
  • 12.7 Other End Users

13 Global Precision Medicine Market, By Distribution Channel

  • 13.1 Direct Sales
  • 13.2 Third-Party Distributors
  • 13.3 Online Platforms

14 Global Precision Medicine Market, By Geography

  • 14.1 North America
    • 14.1.1 United States
    • 14.1.2 Canada
    • 14.1.3 Mexico
  • 14.2 Europe
    • 14.2.1 United Kingdom
    • 14.2.2 Germany
    • 14.2.3 France
    • 14.2.4 Italy
    • 14.2.5 Spain
    • 14.2.6 Netherlands
    • 14.2.7 Belgium
    • 14.2.8 Sweden
    • 14.2.9 Switzerland
    • 14.2.10 Poland
    • 14.2.11 Rest of Europe
  • 14.3 Asia Pacific
    • 14.3.1 China
    • 14.3.2 Japan
    • 14.3.3 India
    • 14.3.4 South Korea
    • 14.3.5 Australia
    • 14.3.6 Indonesia
    • 14.3.7 Thailand
    • 14.3.8 Malaysia
    • 14.3.9 Singapore
    • 14.3.10 Vietnam
    • 14.3.11 Rest of Asia Pacific
  • 14.4 South America
    • 14.4.1 Brazil
    • 14.4.2 Argentina
    • 14.4.3 Colombia
    • 14.4.4 Chile
    • 14.4.5 Peru
    • 14.4.6 Rest of South America
  • 14.5 Rest of the World (RoW)
    • 14.5.1 Middle East
      • 14.5.1.1 Saudi Arabia
      • 14.5.1.2 United Arab Emirates
      • 14.5.1.3 Qatar
      • 14.5.1.4 Israel
      • 14.5.1.5 Rest of Middle East
    • 14.5.2 Africa
      • 14.5.2.1 South Africa
      • 14.5.2.2 Egypt
      • 14.5.2.3 Morocco
      • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

  • 15.1 Industry Value Network and Supply Chain Assessment
  • 15.2 White-Space and Opportunity Mapping
  • 15.3 Product Evolution and Market Life Cycle Analysis
  • 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

  • 16.1 Mergers and Acquisitions
  • 16.2 Partnerships, Alliances, and Joint Ventures
  • 16.3 New Product Launches and Certifications
  • 16.4 Capacity Expansion and Investments
  • 16.5 Other Strategic Initiatives

17 Company Profiles

  • 17.1 Roche Holding AG
  • 17.2 Novartis AG
  • 17.3 Pfizer Inc.
  • 17.4 Johnson & Johnson
  • 17.5 Merck & Co. Inc.
  • 17.6 Thermo Fisher Scientific Inc.
  • 17.7 Illumina Inc.
  • 17.8 Abbott Laboratories
  • 17.9 Danaher Corporation
  • 17.10 Siemens Healthineers AG
  • 17.11 Bio-Rad Laboratories Inc.
  • 17.12 Agilent Technologies Inc.
  • 17.13 Quest Diagnostics Incorporated
  • 17.14 Guardant Health Inc.
  • 17.15 Exact Sciences Corporation
  • 17.16 Foundation Medicine Inc.
  • 17.17 Bristol-Myers Squibb Company
  • 17.18 AstraZeneca PLC

List of Tables

  • Table 1 Global Precision Medicine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Precision Medicine Market Outlook, By Component (2023-2034) ($MN)
  • Table 3 Global Precision Medicine Market Outlook, By Software (2023-2034) ($MN)
  • Table 4 Global Precision Medicine Market Outlook, By Hardware (2023-2034) ($MN)
  • Table 5 Global Precision Medicine Market Outlook, By Services (2023-2034) ($MN)
  • Table 6 Global Precision Medicine Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 7 Global Precision Medicine Market Outlook, By Consumables (2023-2034) ($MN)
  • Table 8 Global Precision Medicine Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 9 Global Precision Medicine Market Outlook, By Assays & Kits (2023-2034) ($MN)
  • Table 10 Global Precision Medicine Market Outlook, By Technology (2023-2034) ($MN)
  • Table 11 Global Precision Medicine Market Outlook, By Genomics (2023-2034) ($MN)
  • Table 12 Global Precision Medicine Market Outlook, By Transcriptomics (2023-2034) ($MN)
  • Table 13 Global Precision Medicine Market Outlook, By Epigenomics (2023-2034) ($MN)
  • Table 14 Global Precision Medicine Market Outlook, By Bioinformatics (2023-2034) ($MN)
  • Table 15 Global Precision Medicine Market Outlook, By Big Data Analytics (2023-2034) ($MN)
  • Table 16 Global Precision Medicine Market Outlook, By Companion Diagnostics (2023-2034) ($MN)
  • Table 17 Global Precision Medicine Market Outlook, By Drug Discovery Technologies (2023-2034) ($MN)
  • Table 18 Global Precision Medicine Market Outlook, By Biomarker Detection (2023-2034) ($MN)
  • Table 19 Global Precision Medicine Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 20 Global Precision Medicine Market Outlook, By Sequencing Technology (2023-2034) ($MN)
  • Table 21 Global Precision Medicine Market Outlook, By Sequencing by Synthesis (2023-2034) ($MN)
  • Table 22 Global Precision Medicine Market Outlook, By Ion Semiconductor Sequencing (2023-2034) ($MN)
  • Table 23 Global Precision Medicine Market Outlook, By Sequencing by Ligation (2023-2034) ($MN)
  • Table 24 Global Precision Medicine Market Outlook, By Pyrosequencing (2023-2034) ($MN)
  • Table 25 Global Precision Medicine Market Outlook, By Single Molecule Real-Time Sequencing (2023-2034) ($MN)
  • Table 26 Global Precision Medicine Market Outlook, By Chain Termination Sequencing (2023-2034) ($MN)
  • Table 27 Global Precision Medicine Market Outlook, By Nanopore Sequencing (2023-2034) ($MN)
  • Table 28 Global Precision Medicine Market Outlook, By Therapeutic Approach (2023-2034) ($MN)
  • Table 29 Global Precision Medicine Market Outlook, By Targeted Therapy (2023-2034) ($MN)
  • Table 30 Global Precision Medicine Market Outlook, By Immunotherapy (2023-2034) ($MN)
  • Table 31 Global Precision Medicine Market Outlook, By Gene Therapy (2023-2034) ($MN)
  • Table 32 Global Precision Medicine Market Outlook, By Cell Therapy (2023-2034) ($MN)
  • Table 33 Global Precision Medicine Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 34 Global Precision Medicine Market Outlook, By Other Therapeutic Approaches (2023-2034) ($MN)
  • Table 35 Global Precision Medicine Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 36 Global Precision Medicine Market Outlook, By Oral (2023-2034) ($MN)
  • Table 37 Global Precision Medicine Market Outlook, By Injectable (2023-2034) ($MN)
  • Table 38 Global Precision Medicine Market Outlook, By Application (2023-2034) ($MN)
  • Table 39 Global Precision Medicine Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 40 Global Precision Medicine Market Outlook, By Neurology (2023-2034) ($MN)
  • Table 41 Global Precision Medicine Market Outlook, By Immunology (2023-2034) ($MN)
  • Table 42 Global Precision Medicine Market Outlook, By Respiratory Diseases (2023-2034) ($MN)
  • Table 43 Global Precision Medicine Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 44 Global Precision Medicine Market Outlook, By Cardiology (2023-2034) ($MN)
  • Table 45 Global Precision Medicine Market Outlook, By Gastroenterology (2023-2034) ($MN)
  • Table 46 Global Precision Medicine Market Outlook, By Rare Genetic Diseases (2023-2034) ($MN)
  • Table 47 Global Precision Medicine Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 48 Global Precision Medicine Market Outlook, By End User (2023-2034) ($MN)
  • Table 49 Global Precision Medicine Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 50 Global Precision Medicine Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 51 Global Precision Medicine Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 52 Global Precision Medicine Market Outlook, By Diagnostic Companies (2023-2034) ($MN)
  • Table 53 Global Precision Medicine Market Outlook, By Research & Academic Institutes (2023-2034) ($MN)
  • Table 54 Global Precision Medicine Market Outlook, By Healthcare IT Companies (2023-2034) ($MN)
  • Table 55 Global Precision Medicine Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 56 Global Precision Medicine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 57 Global Precision Medicine Market Outlook, By Direct Sales (2023-2034) ($MN)
  • Table 58 Global Precision Medicine Market Outlook, By Third-Party Distributors (2023-2034) ($MN)
  • Table 59 Global Precision Medicine Market Outlook, By Online Platforms (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.